Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC-BC-819)
A Multi-Center, Open-Label, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
Sponsor: Anchiano Therapeutics Israel Ltd.
Terminated
Due to Sponsor's decision, only 12 patients were randomized \& completed study.
Other terminated trials from Anchiano Therapeutics Israel Ltd.
More terminations from Anchiano Therapeutics Israel Ltd.
This PHASE2 trial investigates Pancreas, Adenocarcinoma and is currently terminated or withdrawn. Anchiano Therapeutics Israel Ltd. leads this study, which shows 11 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Apr 2019 — Dec 2019 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Feb 2019 — Apr 2019 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anchiano Therapeutics Israel Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .